700 patients110,866 observations180 daysLIVE
← Patients

Patient P-02321

Synthetic patientMETA-24 · Day 168 · 55–64 · F · baseline S17Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
40%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 started — Baseline state S17
  2. Day 25 Trajectory diverged from prediction — Observed response fell below the model's expected path.
  3. Day 122 GI-04 recommended — GI Support Protocol GI-04
  4. Day 123 Patient accepted — Started GI-04 in the companion
  5. Day 131 GI symptom burden −28% vs expected — GI Support Protocol GI-04
  6. Day 137 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 25.

Primary contributors, last 14 days
  • Toxicity-9
  • GI instability-8
  • Inflammatory activity-5

What helped?

  • GI Support Protocol GI-04Day 122
    Result: symptom burden −28%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
59%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 80% showed improvement
  • median effect visible after 5 days
View similar patientsSimulateAdd to intervention cohortAll evidence

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
59 min
worsening · -4.0 vs previous 14 d
Sleep duration
Wearable
6.4 h
worsening · -0.4 vs previous 14 d
Energy level
Daily log
3.7/10
worsening · -0.9 vs previous 14 d
Steps
Wearable
6,758
worsening · -388 vs previous 14 d
GI burden
Companion
39.1/100
worsening · +17.2 vs previous 14 d
Adherence
Companion
73.8 %
stable · -1.8 vs previous 14 d
Sleep quality
Wearable
39.3/100
worsening · -9.5 vs previous 14 d
Glucose, CGM daily mean
CGM
133 mg/dL
worsening · +7.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 48 from the failing basin, 39 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 24 similar · onset 3 d · confidence 59%
  • SC-12 Supportive Compound
    83% improved among 18 similar · onset 6 d · confidence 59%
  • NP-02 Dietary Support Protocol
    65% improved among 20 similar · onset 10 d · confidence 59%
  • More protein
    GI -7.8 next day on high-intake days · n 17
Would not help
  • Keep fat low
    GI +6.3 next day on high-intake days · n 17
  • Keep caffeine low
    GI +5.4 next day on high-intake days · n 24
  • Keep alcohol low
    GI +5.3 next day on high-intake days · n 26
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -7.8supporter · 95%
  • Dietary fat load
    +6.3detractor · 95%
  • Caffeine
    +5.4detractor · 95%
  • Alcohol
    +5.3detractor · 95%
  • Insoluble fibre
    -1.7no signal · 31%
  • Histamine load
    +0.7no signal · 15%
  • Simple carbohydrates
    +0.2no signal · 15%
  • Ultra-processed food
    -0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production ↓80
    • MicrobiomeButyrate capacity 44/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure ↑60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 45
  • Inflammatory signalling ↓45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 44
  • Autonomic recovery ↑45
    • WearableResting HR 76 bpm
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 3.2 · butyrate capacity 44/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
39 ms
Sleep
5.9 h
Steps
6,505
Resting HR
80 bpm
Daily log: GI score 39, nutritional resilience 47, adherence 74.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • No additional supplements this week
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
PatientSimilarityBaselineInterventionOutcomeResponse today
P-0207843%S04——56
P-0200941%S08CR-01improved64
P-0205440%S01CR-01improved57
P-0222940%S20——56
P-0230940%S09——67
P-0215439%S16CR-01improved57
P-0216039%S03——45
P-0223339%S16CR-01improved66
P-0217638%S14GI-04improved52
P-0228737%S03NP-02no change59
P-0257737%S10——56
P-0265937%S09——69